Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

OTHER: Locteron (controlled-release interferon alpha 2b)
BIOLOGICAL: pegylated IFNa2b

Sponsor

Biolex Therapeutics, Inc.